Last 3,199 INR
Change Today +48.20 / 1.53%
Volume 499.2K
DRRD On Other Exchanges
Symbol
Exchange
New York
Natl India
Frankfurt
Mexico
As of 6:05 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

dr. reddy's laboratories (DRRD) Snapshot

Open
3,180
Previous Close
3,151
Day High
3,221
Day Low
3,165
52 Week High
12/1/14 - 3,666
52 Week Low
05/19/14 - 2,247
Market Cap
544.8B
Average Volume 10 Days
437.5K
EPS TTM
126.52
Shares Outstanding
170.3M
EX-Date
07/11/14
P/E TM
25.3x
Dividend
18.00
Dividend Yield
0.56%
Current Stock Chart for DR. REDDY'S LABORATORIES (DRRD)

Related News

No related news articles were found.

dr. reddy's laboratories (DRRD) Related Businessweek News

No Related Businessweek News Found

dr. reddy's laboratories (DRRD) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company in India. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment is also engaged in the operation of biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment is involved in the discovery and development of new chemical entities and differentiated formulations for subsequent commercialization. Its differentiated formulations portfolio consists of new, synergistic combinations, and technologies that enhance safety and/or efficacy by modifying pharmacokinetics of existing medicines. This segment is also involved in the Company’s specialty pharmaceuticals business, which conducts sales and marketing operations for in-licensed and co-developed dermatology products. The company’s therapeutic categories include gastro-intestinal, cardiovascular, pain management, and oncology. It also operates in North America, Europe, Russia, other countries of the former Soviet Union, and internationally. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

18,421 Employees
Last Reported Date: 06/26/14
Founded in 1984

dr. reddy's laboratories (DRRD) Top Compensated Officers

Co-Chairman, Chief Executive Officer, Member ...
Total Annual Compensation: 6.3M
Chairman of The Board, Member of The Manageme...
Total Annual Compensation: 7.7M
Compensation as of Fiscal Year 2014.

dr. reddy's laboratories (DRRD) Key Developments

Dr. Reddy’s Laboratories Launches Valganciclovir Tablets USP 450 mg

Dr. Reddy’s Laboratories announced that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of VALCYTE® (Valganciclovir) tablets in the US market on December 15, 2014, approved by the United States Food & Drug Administration (USFDA). Dr. Reddy’s Valganciclovir tablets, USP in 450 mg is available in bottle counts of 60.

Dr. Reddy's Laboratories Ltd. Launches Docetaxel Injection USP

Dr. Reddy's Laboratories announced that is has launched Docetaxel Injection USP 20 mg/mL and 80 mg/4 mL a therapeutic equivalent generic version of TAXOTERE(R) (docetaxel Injection) in the US market on November 21, 2014. Dr. Reddy's ANDA is approved by the United States Food & Drug Administration (USFDA). Dr. Reddy's Docetaxel Injection USP, 20 mg/mL and 80 mg/4 mL are available as a single dose, one vial formulation that does NOT require a prior dilution with a diluent and is ready to add to the Intravenous Infusion solution.

Dr. Reddy’s Laboratories Launches its Over-The-Counter Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets

Dr. Reddy’s Laboratories announced that it has launched its over-the-counter (OTC) Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg /120 mg, a bioequivalent generic version of Allegra-D® 12 Hour Allergy & Congestion, in the U.S. market on November 18, 2014. Dr. Reddy’s ANDA is approved by the United States Food & Drug Administration (USFDA). The Allegra-D® 12 Hour brand has U.S. sales of approximately $49.8 million for the latest 52 weeks ending October 6, 2014 for Total US Multi Outlet according to IRI. Dr. Reddy’s Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended Release Tablets 60 mg /120 mg is available in a 20 count blister.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRRD:IN 3,199.45 INR +48.20

DRRD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cipla Ltd/India 618.95 INR -6.40
Croda International PLC 2,607 GBp -41.00
Endo International PLC $71.38 USD +0.07
Lupin Ltd 1,418 INR -7.50
Symrise AG €49.42 EUR -0.007
View Industry Companies
 

Industry Analysis

DRRD

Industry Average

Valuation DRRD Industry Range
Price/Earnings 23.7x
Price/Sales 3.7x
Price/Book 5.3x
Price/Cash Flow 23.6x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DR. REDDY'S LABORATORIES, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.